Framework Engineering Research

An open index of evidence, theory, and practice

research-document

Handoff — FE-BOUNDARY-001

Research Area
General Research
Status
draft
Version
0.1
Priority
medium
Updated
2026-07-22
Source
research/framework-engineering/ros-profile/executions/openai-codex/2026-07-28/FE-BOUNDARY-001/HANDOFF.md

Handoff — FE-BOUNDARY-001

Status: complete; ready for review, not canonical promotion.

Objective

Determine the defensible boundary and classification of Framework Engineering relative to adjacent disciplines and prepare a research-to-engineering operating path.

Completed

  • Frozen comparison and decision rules.
  • Full comparator and institutional-maturity source coverage.
  • Strongest-case and full-subsumption analysis.
  • Current and normative definition split.
  • FEH-001 confidence update.
  • Profile v1.0 audit and proposed v1.1 controls.
  • Matched-utility experiment design.
  • Successor REP and machine-readable evidence.
  1. research/evaluations/FE-BOUNDARY-2026-07-28/README.md
  2. research/evaluations/FE-BOUNDARY-2026-07-28/RP-FE-BOUNDARY-2026-07-28.md
  3. research/evaluations/FE-BOUNDARY-2026-07-28/next-experiment.md
  4. research/evaluations/FE-BOUNDARY-2026-07-28/ros-fe-profile-v1-audit.md

Decision state

  • Present classification: repository research program + candidate integrated engineering profile.
  • Distinct-discipline interpretation: not supported.
  • Individual full subsumption: not established.
  • Collective functional subsumption: substantially supported.
  • Deciding unknown: incremental outcome value net of lifecycle cost.
  • Controlling experiment: EX-FE-0002 remains Stage A incomplete, Stage B blocked, and classification inconclusive.

Next action

Use the source packet to repair and complete or formally supersede EX-FE-0002. Then obtain independent systems/method engineering and quantitative-method review, freeze power and thresholds, implement only the v1.1 P0 integrity controls needed for the study, and preregister the artificial matched comparison.

Scientific constraints

No theory promotion, Stage B authorization, efficacy claim, human-validation claim, cross-provider-replication claim, or silent v1.0 mutation follows from this execution.